Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells

Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson’s disease: Involvement of antioxidative enzymes induction

“…Consistent with other studies, Mei et al indicated that neurotrophic factor prevented the apoptosis of PC12 cells induced by 6-OHDA through upregulation of Bcl-2/Bax ratio and downregulation of caspase-3activity [38]. Luteolin protected PC12 cells against 6-OHDA-induced apoptosis via suppressing the induction of Bax, inhibiting the reduction of Bcl-2, and reducing the induction of Bax/Bcl-2 ratio [39]. However, O'Malley et al suggested that 6-OHDA-induced neurotoxicity is not regulated by Bcl-2 in primary mice dopaminergic neurons cells [40].…”

Neuroprotective effects of macranthoin G from Eucommia ulmoides against hydrogen peroxide-induced apoptosis in PC12 cells via inhibiting NF-κB activation

“…The mitochondria-dependent pathway of apoptosis is regulated by members of the Bcl-2 family of proteins [29,30]. It has been demonstrated that increased Bax and lowered Bcl-2 expression play a critical role in reducing mitochondrial membrane potential and increasing ROS production in neurons [31,32]. Therefore, we investigated whether regulation of Bcl-2 family was involved in MCG-mediated reduction of ROS in H 2 O 2 -stimulated PC12 cells.…”

Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors

“…As 6-OHDA shares certain structural similarities with DA, it can enter dopaminergic neurons via DA transporters, and consequently cause toxicity (Shi et al, 2011). It produces diverse toxic effects, such as mitochondrial dysfunction and oxidative stress, apoptosis, neuroinflammation, and dopaminergic cell death (Chan et al, 2009; Liang et al, 2011; Shi et al, 2011; Thornton and Vink, 2012; Guo et al, 2013; Pyo et al, 2013; Wang J. Y. et al, 2013; Elyasi et al, 2014; Magalingam et al, 2014; Mu et al, 2014; De Jesús-Cortés et al, 2015; Liu et al, 2015; Yan et al, 2015; Zhang et al, 2015; Mirzaie et al, 2016). Disturbance of the dopaminergic system may also cause glutamatergic NMDARs imbalances in the brain (Hallett et al, 2006).…”